Altimmune announced key results from its RECLAIM Phase 2 trial of pemvidutide, a dual glucagon/GLP-1 receptor agonist, showing significant reduction in heavy drinking days in adults with moderate-to-severe alcohol use disorder. The trial met primary and FDA-validated secondary endpoints with good tolerability. These results will be presented at AASLD's The Liver Meeting 2026, with an End-of-Phase 2 meeting with the FDA planned for December to discuss Phase 3 development. This progress highlights pemvidutide's potential as a novel treatment for alcohol use disorder and related liver diseases.
Altimmune's pemvidutide trial results provide context for health sector trends. Of 150 health stocks on Pluang, 88 rose and 58 fell today. Notable movers include ADPT at USD 28.06 with a 5.05% gain and 100% buy order activity, BDX at USD 199.00 down 4.87% with 100% sell activity, and TXG at USD 64.26 down 4.83% with 92% buy activity. Data is as of Nov 05, 2026 20:51 WIB.
Global tech giants like Amazon, Google, and Microsoft are committing hundreds of billions of dollars to expand AI-focused data center accelerators, driven by surging demand from generative AI workloads that exceed traditional CPU capabilities. These ...
Berkshire Hathaway's stock portfolio is now worth about three times what the company originally paid for it. These gains alone represent roughly 19% of Berkshire Hathaway's total company value, highlighting the significant growth and value generated ...
C3is Inc. will implement a one-for-five reverse stock split effective November 9, 2026, reducing its outstanding shares from about 4.2 million to 0.84 million. This move aims to increase the stock price to meet Nasdaq's minimum bid price requirement ...
Firmly secured $15 million in a Series A funding round led by Squarepoint Capital, with participation from J.P. Morgan Payments, Mastercard, and Samsung NEXT. The company provides a no-code platform that connects merchants to AI-driven shopping chann...
On November 4, 2026, Shell plc repurchased a total of 1,876,276 shares across multiple trading venues including LSE, Chi-X, BATS, XAMS, CBOE, and TQEX. The shares were bought at prices ranging from £37.98 to £38.82 and €45.70 to €46.72, with an avera...
